Bevacizumab

ChemicalBook > CAS DataBase List > Bevacizumab

Product Name: Bevacizumab
CAS No.: 216974-75-3
Chemical Name: Bevacizumab
Synonyms: Avastin;Avastatin;Bevacizumab;Rhumab-vegf;Bevacituzumab;Unii-2S9zzm9Q9v;Bevacizumab Impurity;Bevacizumab (Avastin);Bevacizumab USP/EP/BP;BevacizuMab [USAN:INN]
CBNumber: CB3966244
Molecular Formula: C6638H10160N1720O2108S44
Formula Weight: 0
MOL File: Mol file

Less

Bevacizumab Property

storage temp.: Store at -80°C
solubility: Soluble in DMSO

Less

Safety

Hazardous Substances Data: 216974-75-3(Hazardous Substances Data)

Less

Hazard and Precautionary Statements (GHS)

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: 1445547
Product name: USP mAb 002, Monoclonal IgG1
Purity: United States Pharmacopeia (USP) Reference Standard
Packaging: 2MG
Price: $1370
Updated: 2024/03/01

Biosynth Carbosynth

Product number: FB76708
Product name: Bevacizumab - 25mg/ml solution in PBS
Packaging: 25mg
Price: $1875
Updated: 2021/12/16

ChemScene

Product number: CS-7820
Product name: Bevacizumab
Purity: ≥99.0%
Packaging: 25mg
Price: $2500
Updated: 2021/12/16

ChemScene

Product number: CS-7820
Product name: Bevacizumab
Purity: ≥99.0%
Packaging: 50mg
Price: $4000
Updated: 2021/12/16

Biosynth Carbosynth

Product number: FB76708
Product name: Bevacizumab - 25mg/ml solution in PBS
Packaging: 1mg
Price: $150
Updated: 2021/12/16

Less

Bevacizumab Chemical Properties,Usage,Production

Description

Bevacizumab, a humanized IgG1 monoclonal antibody against vascular endothelial growth factor (VEGF), inhibits tumor angiogenesis and delays disease progression. It was launched in the US as an intravenous infusion for the treatment of metastatic colorectal cancer in combination with fluorouracil-based chemotherapy. Bevacizumab was developed by engineering the VEGF binding residues of the murine neutralizing antibody A.4.6.1 into the framework of the consensus human IgG1. Its amino acid sequence is approximately 93% human IgG and 7% murine antibody and is produced in a CHO cell expression system. Bevacizumab binds VEGF with high affinity (K_d=0.5 nM) and prevents its interaction with tyrosine kinase receptors VEGFR1 and VEGFR2 on the surface of endothelial cells, thereby inhibiting cell proliferation and microvascular growth. In mouse models, administration of bevacizumab blocked the growth of human tumor xenografts and reduced the size and number of metastases. The recommended dosage of bevacizumab is 5 mg/kg administered once every 2 weeks as an intravenous infusion until disease progression is detected. Based on a population pharmacokinetic analysis of patients who received 1–20 mg/kg of bevacizumab once every 1–3 weeks, the estimated half-life was approximately 20 days, and the predicted time to reach steady state was 100 days. The maximum and minimum steady-state serum concentrations at 2.5 mg/kg/week dose were 226 and 88 μg/mL, respectively. Clearance of bevacizumab is low, and varies with body weight, gender and tumor burden. In patients with colorectal cancer receiving bevacizumab 5–10 mg/kg in combination with fluorouracil and leucovorin, mean total clearance was 2.79 ml/kg/day. In clinical studies involving the administration of bevacizumab (5 mg/kg every 2 weeks) or placebo in addition to bolus-IFL (irinotecan 125 mg/m² i.v., 5-fluorouracil 500 mg/ m² i.v., and leucovorin 20 mg/m² i.v. administered once weekly for four weeks every six weeks), the median overall survival was significantly increased from 15.6 months in the bolus IFL + placebo arm to 20.3 months in the bolus IFL + bevacizumab arm. Similar increases were also seen in progression-free survival (6.4 versus 10.6 months), overall response rate (35% versus 45%), and duration of response (7.1 months versus 10.4 months). The most common adverse events in these trials were hypertension, diarrhea and leucopenia. Other clinically significant adverse events reported occasionally were gastrointestinal perforations, thromboembolic events, bleeding and proteinuria. Because wound healing may be impaired by inhibition of VEGF, bevacizumab therapy is not recommended until 28 days after primary surgery.

Originator

Genentech (US)

brand name

Avastin

Clinical Use

Monoclonal antibody:

Treatment of colorectal cancer

Treatment of breast cancer

Treatment of renal cell carcinoma

Treatment of lung cancer

Treatment of ovarian, fallopian tube or peritoneal cancer

Enzyme inhibitor

This humanized monoclonal antibody (MW = 149.2 kDa; CAS 216974-75- 3), known by the tradename Avastinò, is an angiogenesis inhibitor that targets vascular endothelial growth factor A (VEGF-A). Because VEGF is the key angiogenic factor in tumors, blocking VEGF signal transduction can lead to tumor growth arrest and inhibition of metastasis. The rationale for Avastin therapy is premised on findings that high VEGF expression correlates with (a) reduced overall survival, (b) disease progression, (c) greater risk of relapse, (d) lymph node involvement, and (e) malignant pleural effusion. By binding directly bind to VEGF-A, Avastin blocks its interaction with endothelial cell VEGF receptors, thereby inhibiting neovascularization and depriving cancer cells of vital nutrients and oxygen. Avastin is approved for: metastatic colorectal cancer (mCRC), when started with the first or second intravenous 5-FU–based chemotherapy for metastatic cancer; advanced-stage nonsquamous, non–small cell lung cancer (NSCLC), when administered in combination with carboplatin and paclitaxel in patients who have not received chemotherapy for their advanced disease; metastatic renal cell cancer (mRCC) when used with interferon-a; and glioblastoma multiforme (GBM) in adult patients whose cancer has progressed after prior treatment.

target

Angiogenesis is important for tumour growth and metastasis, and is an important target for new biological agents. Bevacizumab is a humanised recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding, and inhibits angiogenesis and tumour growth.

Drug interactions

Potentially hazardous interactions with other drugs
Bisphosphonates: increased risk of osteonecrosis of the jaw.
Cytotoxics: avoid with panitumumab.
Vaccines: risk of generalised infections with live vaccines - avoid.

Metabolism

Assessment of bevacizumab metabolism in rabbits following a single IV dose of 125I-bevacizumab indicated that its metabolic profile was similar to that expected for a native IgG molecule which does not bind VEGF. The metabolism and elimination of bevacizumab is similar to endogenous IgG i.e. primarily via proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver. Binding of the IgG to the FcRn receptor results in protection from cellular metabolism and the long terminal half-life.

Bevacizumab Preparation Products And Raw materials

Raw materials

Preparation Products

Less

Bevacizumab Suppliers

China 128 India 2 United Kingdom 1 United States 5 Global 136

Shanghai Aladdin Biochemical Technology Co.,Ltd.

Tel: +86-18521732826
Email: market@aladdin-e.com
Country: China
ProdList: 48467
Advantage: 58

Hefei Hirisun Pharmatech Co., Ltd.

Tel: +86-0551-62678551 +86-15056975894
Fax: 0551-62678551
Email: sales@hirisunpharm.com
Country: China
ProdList: 180
Advantage: 55

Taizhou KEDE Chemical Co., Ltd

Tel: 0576-84613060 13093829633
Fax: 0576-84613060
Email: sales@kedechemical.com
Country: China
ProdList: 298
Advantage: 60

Hubei Zhongshan Medical Technology Co., Ltd

Tel: 027-61907345 13397111514
Fax: 3443707954
Email: w13397111514@163.com
Country: China
ProdList: 1011
Advantage: 58

Shanghai jerryxing Biomedical Technology Co., Ltd

Tel: 17721492509
Email: 643638326@qq.com
Country: China
ProdList: 5347
Advantage: 58

Chembest Research Laboratories Limited

Tel: 021-20908456
Fax: 021-58180499
Email: sales@BioChemBest.com
Country: China
ProdList: 6011
Advantage: 61

Nanjing Chemlin Chemical Co., Ltd

Tel: 025-83697070
Fax: +86-25-83453306
Email: info@chemlin.com.cn
Country: China
ProdList: 17989
Advantage: 64

Wuhan Sunrise Technology Development Co., Ltd.

Tel: 027-027-83314682 13554138826
Fax: +86 (27) 8331-4682
Email: whsrtech@vip.163.com
Country: China
ProdList: 300
Advantage: 62

Hunan Hui Bai Shi Biotechnology Co., Ltd.

Tel: 0731-85526065 13308475853
Email: ivy@hnhbsj.com
Country: China
ProdList: 4550
Advantage: 62

Wuhan Fortuna Chemical Co., Ltd

Tel: 027-027-59207852 13308628970
Fax: QQ3130921841
Email: buy@fortunachem.com
Country: China
ProdList: 2893
Advantage: 58

Dalian Meilun Biotech Co., Ltd.

Tel: 0411-62910999 13889544652
Email: sales@meilune.com
Country: China
ProdList: 4654
Advantage: 58

Beijing HuaMeiHuLiBiological Chemical

Tel: 010-56205725
Fax: 010-65763397
Email: waley188@sohu.com
Country: China
ProdList: 12338
Advantage: 58

Shanghai Topbiochem Technology Co., Ltd

Tel: 021-58170097
Email: info@topbiochem.com
Country: China
ProdList: 9452
Advantage: 58

NCE Biomedical Co.,Ltd.

Tel: 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax: +86-27-87599188
Country: China
ProdList: 1494
Advantage: 55

TargetMol Chemicals Inc.

Tel: 021-021-33632979 15002134094
Fax: 021-33632979
Email: marketing@targetmol.com
Country: China
ProdList: 7854
Advantage: 58

ShangHai Caerulum Pharma Discovery Co., Ltd.

Tel: 18149758185
Email: sales-cpd@caerulumpharma.com
Country: China
ProdList: 3421
Advantage: 58

Shanghai Macklin Biochemical Co.,Ltd.

Tel: 15221275939 15221275939
Fax: 021-50706099
Email: shenlinxing@macklin.cn
Country: China
ProdList: 15878
Advantage: 55

LUCKY PHARMA CO., LIMITED

Tel: 0571-86403260 86403970
Fax: 0571-86403970
Email: lucky@lkbiology.com
Country: China
ProdList: 243
Advantage: 58

LETOPHARM LIMITED

Tel: +86-21-5821 5861
Fax: +86-21-5106 2861
Email: sales@letopharm.com
Country: China
ProdList: 2384
Advantage: 58

Chizhou Kailong Import and Export Trade Co., Ltd.

Tel
Fax: -
Email: xg01_gj@163.com
Country: China
ProdList: 9503
Advantage: 50

Shanghai Lollane Biological Technology Co.,Ltd.

Tel: 021-52996696，15000506266 15000506266
Fax: +86-21-52996696
Country: China
ProdList: 4153
Advantage: 55

Shanghai Synchem Pharma Co., ltd

Tel: 021-61984905-1 18016477331
Email: synchempharma@aliyun.com
Country: China
ProdList: 6455
Advantage: 55

Hui Chem Co., Ltd.

Tel: 021-34799779 18918539052
Fax: 021-61916468
Email: 1879902218@qq.com
Country: China
ProdList: 77
Advantage: 55

Shanghai Hanjing Chemicals Co., Ltd.

Tel: 021-54285032 13641685631
Fax: +86 (21) 5443 7651
Email: gerry.shu@hanjingchemicals.com
Country: China
ProdList: 76
Advantage: 55

Pharmacodia (Beijing) Co.,Ltd

Tel: +86-400-851-9921
Fax: +86-10-82826195
Email: sales@pharmacodia.com
Country: China
ProdList: 2317
Advantage: 55

Shanghai EFE Biological Technology Co., Ltd.

Tel: 021-65675885 18964387627
Fax: 021-65675885
Email: info@efebio.com
Country: China
ProdList: 9709
Advantage: 58

ShangHai Biochempartner Co.,Ltd

Tel: 17754423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8011
Advantage: 62

Shanghai Rechem science Co., Ltd.

Tel: 21-31433387 15618786686
Fax: QQ:1369748377
Email: sales@rechemscience.com
Country: China
ProdList: 2989
Advantage: 58

Beijing Jin Ming Biotechnology Co., Ltd.

Tel: 010-60605840 18892239720
Fax: 010-60605840
Email: psaitong@jm-bio.com
Country: China
ProdList: 12308
Advantage: 58

Wuhan Wsem Biological Co., Ltd.

Tel: 027-83778876 13667159345
Fax: 027-83778876
Email: 13667159345@163.com
Country: China
ProdList: 1942
Advantage: 55

Wellman Pharmaceutical Group Limited

Tel: 027-027-83778875 15807197853
Fax: 027-83991220
Email: 15807197853@163.com
Country: China
ProdList: 3978
Advantage: 58

Chemleader Biomedical Co., Limited.

Tel: 021-58180488
Fax: 021-58180499
Email: sales@MedChemLeader.com
Country: China
ProdList: 999
Advantage: 58

Twochem Co.Ltd.

Tel: 021-58111628 15800915896
Fax: QQ 3285589261
Country: China
ProdList: 1988
Advantage: 58

Jinan Yaoyan Pharmaceutical Co., Ltd.

Tel
Fax: -
Email: jnyaoyan@163.com
Country: China
ProdList: 3069
Advantage: 58

Zhengzhou Acme Chemical Co., Ltd.

Tel: 0371-037163312495,13303845143 13303845143
Fax: QQ3001379618
Email: 3001379618@qq.com
Country: China
ProdList: 9945
Advantage: 58

Taizhou Crene Biotechnology Co. Ltd.

Tel: 0576-88813233 13396860566
Email: sales@pharm-intermediates.com
Country: China
ProdList: 2013
Advantage: 58

Nanjing Meihao Pharmaceutical Technology Co., Ltd.

Tel: meitaochem@126.com
Email: meitaochem@126.com
Country: China
ProdList: 19105
Advantage: 58

Wuhan Fortuna Chemical Co., Ltd

Tel: +86-27-59207850 +86-13986145403
Fax: 86-27-59524646
Email: info@fortunachem.com
Country: China
ProdList: 5998
Advantage: 58

Zhejiang J&C Biological Technology Co.,Limited

Tel: +1-2135480471 +1-2135480471
Email: sales@sarms4muscle.com
Country: China
ProdList: 10523
Advantage: 58

Hangzhou Proserre Chemical Co.,Ltd.

Tel: +86-571-86088112
Email: info@proserre.com
Country: China
ProdList: 1077
Advantage: 58

Hubei Ipure Biology Co., Ltd

Tel: +8613367258412
Fax: 18062427325
Email: ada@ipurechemical.com
Country: China
ProdList: 10326
Advantage: 58

Hangzhou Huarong Pharm Co., Ltd.

Tel: 571-86758373 +8613588754946
Fax: 0086-571-81131109
Email: sales@huarongpharm.com
Country: CHINA
ProdList: 3149
Advantage: 58

Hefei Hirisun Pharmatech Co., Ltd

Tel: +8615056975894
Fax: 86-0551-62678551
Email: shawn@hirisunpharm.com
Country: CHINA
ProdList: 9923
Advantage: 58

Baoji Guokang Healthchem co.,ltd

Tel: +8615604608665 15604608665
Email: dominicguo@gk-bio.com
Country: CHINA
ProdList: 9427
Advantage: 58

Dideu Industries Group Limited

Tel: +86-29-89586680 +86-15129568250
Email: 1026@dideu.com
Country: China
ProdList: 28608
Advantage: 58

AFINE CHEMICALS LIMITED

Tel: 0571-85134551
Fax: 008657185134895
Email: info@afinechem.com
Country: CHINA
ProdList: 15377
Advantage: 58

Shaanxi Dideu Medichem Co. Ltd

Tel: +86-029-89586680 +86-18192503167
Fax: +86-29-88380327
Email: 1026@dideu.com
Country: China
ProdList: 9126
Advantage: 58

HONG KONG IPURE BIOLOGY CO.,LIMITED

Tel: 86 18062405514 18062405514
Email: ada@ipurechemical.com
Country: CHINA
ProdList: 3465
Advantage: 58

DC Chemicals

Tel: 021-58447131 13564518121
Email: sales@dcchemicals.com
Country: China
ProdList: 9414
Advantage: 58

Changzhou Chenhong Biotechnology Co., Ltd.

Tel: 0519-85788828 13775037613
Email: sales@chemrenpharm.com
Country: China
ProdList: 3553
Advantage: 58

Less

View Lastest Price from Bevacizumab manufacturers

WUHAN FORTUNA CHEMICAL CO., LTD

Product: Bevacizumab 216974-75-3
Price: US $0.00/G
Min. Order: 1G
Purity: 98%min
Supply Ability: 30kg/month
Release date: 2023-02-06

Hangzhou Huarong Pharm Co., Ltd.

Product: Bevacizumab 216974-75-3
Price: US $0.00-0.00/mg
Min. Order: 1mg
Purity: 99%
Supply Ability: 100KG
Release date: 2021-09-15

Dideu Industries Group Limited

Product: Bevacizumab 216974-75-3
Price: US $1.10/g
Min. Order: 1g
Purity: 99.9%
Supply Ability: 100 Tons Min
Release date: 2021-06-11

216974-75-3, BevacizumabRelated Search:

Adalimumab Ustekinumab Nivolumab Daratumumab OMALIZUMAB Lambrolizumab Dulaglutide Infliximab Rituximab Gemcitabine Hydroxyl camptothecine Triamcinolone acetonide Icotinib Ranibizumab Evolocumab Ramucirumab ipilimumab Eculizumab

Avastin

BevacizuMab [USAN:INN]

Anti-vegf monoclonal antibody

Bevacizumab

Immunoglobulin G1, anti-(human vascular endothelial growth factor) (human-mouse monoclonal rhumab-vegf gamma1-chain), disulfide with human-mouse monoclonal rhumab-vegf light chain, dimer

Rhumab-vegf

Unii-2S9zzm9Q9v

Avastatin

Bevacituzumab

Bevacizumab (Avastin)

Bevacizumab - 25mg/ml solution in PBS

Bevacizumab(anti-VEGF)

Bevacizumab USP/EP/BP

Research Grade Bevacizumab(DHD12602)

Bevacizumab, Lyophilized powder

USP mAb 002, Monoclonal IgG1 (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED)

Bevacizumab Impurity

216974-75-3

C6638H10160N1720O2108S44